Soman V, Felig P
J Clin Invest. 1978 Mar;61(3):552-60. doi: 10.1172/JCI108966.
To investigate the role of hepatic glucagon receptors in the hypersensitivity to glucagon observed in insulin-deprived diabetics, liver plasma membranes were prepared from control rats and from streptozotocin-induced diabetic rats some of whom were treated with high-dose and low-dose insulin. The untreated diabetic animals exhibited hyperglycemia, weight loss, hypoinsulinemia, and hyperglucagonemia. High-dose insulin treatment (2 U Protamine-zinc-insulin/100 g per day) resulted in normoglycemia, normal weight gain, mild hyperinsulinemia, and return of glucagon levels toward base line. The low-dose (1 U protamine-zinc-insulin/100 g per day) insulin-treated diabetic group demonstrated chemical changes intermediate between the untreated and the high-dose insulin-treated animals. In liver plasma membranes from the untreated diabetic rats, specific binding of (125)I-glucagon was increased by 95%. Analysis of binding data suggested that the changes in glucagon binding were a consequence of alterations in binding capacity rather than changes in binding affinity. Furthermore, in the untreated diabetic rats, both basal and glucagon (2 muM)-stimulated adenylate cyclase activity were twofold higher than in controls. In the high-dose insulin-treated diabetic rats, glucagon binding and basal and glucagon-stimulated adenylate cyclase activity were normalized to control values, whereas low-dose insulin treatment resulted in changes intermediate between control and untreated diabetic rats. In contrast to glucagon-stimulated adenylate cyclase activity, fluoride-stimulated adenylate cyclase activity was similar in all groups of rats. Liver plasma membranes from untreated and insulin-treated diabetic animals degraded (125)I-glucagon to the same extent as control rats. The specific binding of (125)I-insulin in the untreated diabetic animals was 40% higher than in control rats. In low-dose insulin-treated diabetic rats, insulin binding was not significantly different from that of control rats, whereas in the high-dose insulin-treated group in whom plasma insulin was 70% above control levels, insulin binding was 30% lower than in control rats. These findings suggest that alterations in glucagon receptors may contribute to the augmented glycemic and ketonemic response to glucagon observed in insulin-deprived diabetics.
为研究肝胰高血糖素受体在胰岛素缺乏的糖尿病患者中对胰高血糖素的高敏反应中所起的作用,从对照大鼠以及链脲佐菌素诱导的糖尿病大鼠制备肝细胞膜,其中部分糖尿病大鼠接受高剂量和低剂量胰岛素治疗。未治疗的糖尿病动物表现出高血糖、体重减轻、低胰岛素血症和高胰高血糖素血症。高剂量胰岛素治疗(2U精蛋白锌胰岛素/100g体重/天)导致血糖正常、体重正常增加、轻度高胰岛素血症,且胰高血糖素水平恢复至基线。低剂量(1U精蛋白锌胰岛素/100g体重/天)胰岛素治疗的糖尿病组所表现出的化学变化介于未治疗组和高剂量胰岛素治疗组动物之间。在未治疗的糖尿病大鼠的肝细胞膜中,(125)I-胰高血糖素的特异性结合增加了95%。结合数据分析表明,胰高血糖素结合的变化是结合能力改变的结果,而非结合亲和力的变化。此外,在未治疗的糖尿病大鼠中,基础腺苷酸环化酶活性以及胰高血糖素(2μM)刺激的腺苷酸环化酶活性均比对照大鼠高两倍。在高剂量胰岛素治疗的糖尿病大鼠中,胰高血糖素结合以及基础和胰高血糖素刺激的腺苷酸环化酶活性恢复至对照值,而低剂量胰岛素治疗导致的变化介于对照大鼠和未治疗的糖尿病大鼠之间。与胰高血糖素刺激的腺苷酸环化酶活性不同,氟化物刺激的腺苷酸环化酶活性在所有大鼠组中相似。未治疗和胰岛素治疗的糖尿病动物的肝细胞膜降解(125)I-胰高血糖素的程度与对照大鼠相同。未治疗的糖尿病动物中(125)I-胰岛素的特异性结合比对照大鼠高40%。在低剂量胰岛素治疗的糖尿病大鼠中,胰岛素结合与对照大鼠无显著差异,而在血浆胰岛素比对照水平高70%的高剂量胰岛素治疗组中,胰岛素结合比对照大鼠低30%。这些发现提示,胰高血糖素受体的改变可能导致胰岛素缺乏的糖尿病患者中观察到的对胰高血糖素的血糖和酮体反应增强。